Braveheart Bio
Stories
-
Braveheart Bio registers Phase 3 trial of BHB-1893 in non-obstructive hypertrophic cardiomyopathy
The study plans to enroll an estimated 600 adults with symptomatic non-obstructive hypertrophic cardiomyopathy, beginning in December 2026 and aiming for primary completion in December 2029. Its main purpose is to find out whether BHB-1893 works better than placebo in adults with non-obstructive hypertrophic cardiomyopathy.